Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm ...

A recent study published in JAMA Dermatology has demonstrated that PROMIS measures are valid tools for evaluating the physical, emotional, and social effects of chronic skin diseases.

When COVID hit, health care systems around the world were turned upside down. Hospitals cleared beds, routine appointments ...

InnoCare Pharma Ltd recently said that, driven by robust sales of its flagship anti-cancer drug and income from overseas licensing agreements, it expects to more than double its revenue in 2025 and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.44, expectations were ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Patients with atopic dermatitis (AD) report a desire for climate-health education, which is infrequently addressed by ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...